Amgen (AMGN) Cost of Revenue (2009 - 2026)

Amgen's Cost of Revenue history runs 18 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• In Q1 2026, Cost of Revenue fell 7.55% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $11.8 billion (down 6.44% YoY), while the FY2025 annual figure was $12.0 billion, down 6.39% from the prior year.
• Cost of Revenue for Q1 2026 stood at $2.7 billion, down from $3.0 billion in the prior quarter.
• The five-year high for Cost of Revenue was $3.3 billion in Q3 2024, with the low at $1.5 billion in Q2 2022.
• The 5-year median for Cost of Revenue is $3.0 billion (2025), against an average of $2.5 billion.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue declined 7.76% in 2022, then surged 86.05% in 2024.
• Amgen's Cost of Revenue stood at $1.7 billion in 2022, then soared by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then slipped by 4.37% to $3.0 billion in 2025, then retreated by 7.8% to $2.7 billion in 2026.
• Business Quant data shows AMGN's Cost of Revenue at $2.7 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.1 billion in Q3 2025.